Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India’s Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor.
Tag Archive for: generics
With drug shortages in the U.S. not greatly improving, the Federal Trade Commission and the Department of Health and Human Services announced Wednesday that they are issuing a request for information to look at different groups involved in generic drug supply chains and evaluate how they may be contributing to persistent shortages.
The FDA has approved many different generic versions of Takeda’s blockbuster Vyvanse (lisdexamfetamine dimesylate), used for the treatment of attention-deficit/hyperactivity disorder and binge-eating disorder in adults.
Amgen Inc. convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG’s Sandoz Inc until 2028.
The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp.’s bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China’s HEC Pharm Co. Ltd.
Teva Pharmaceutical Industries, the world’s largest generic drugmaker, met fourth-quarter profit estimates, but its shares fell after its forecast of a largely flat year in 2023 disappointed investors.
Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.
India’s Hetero said on Tuesday that its generic version of Paxlovid, an antiviral treatment for COVID-19 developed by Pfizer Inc., was added to the World Health Organization’s prequalification list, which serves as a benchmark for procurement of medicines by developing countries.
Eli Lilly and Co. on Tuesday forecast its annual profit and revenue below estimates, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
